Induction of human allergen-specific immune regulation following treatment with a combination of Toll-Like Receptor 7 agonist with allergen: an in vit

过敏性鼻炎和哮喘是由对常见吸入性过敏原的异常Th 2型免疫反应性引起的。现有的治疗缓解了炎症，但不能改变疾病的进展。与过敏原免疫耐受的发展和潜在疾病病理生理学的改变相关的唯一治疗方式是过敏原特异性免疫治疗。然而，过敏原免疫疗法有几个局限性，包括需要定期给药数年，这限制了其有效性和广泛应用。为了改善其功效和与能够以受控方式促进的免疫增强剂共同施用的给药方案，已经提出了Th 1和/或调节性T和B细胞应答的产生。

Allergic rhinitis and asthma result from aberrant Th2-type immune reactivity against common inhaled allergens. Existing therapies alleviate symptomatology, but do not offer alteration of disease progress. The only therapeutic modality that has been associated with the development of immune tolerance to allergens and modification of underlying disease pathophysiology is allergen specific immunotherapy. However, allergen immunotherapy has several limitations, including the need of regular administration for several years, that restrict its effectiveness and broad application. To improve its efficacy and dosing regimen co-administration with immunopotentiators capable of promoting in a controlled fashion, the generation of Th1 and/or regulatory T and B cell responses has been proposed.